Jiangsu Aidea Pharmaceutical Group Co., Ltd.
Clinical trials sponsored by Jiangsu Aidea Pharmaceutical Group Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- First human test: can a new drug called ADB116 be given safely? Results expected Dec 2026 (estimated)
- New HIV drug candidate targets resistant strains Results expected Jun 2027 (estimated)
-
New daily pill aims to outperform standard HIV therapy in landmark trial
Disease control Recruiting nowThis study tests a new experimental drug, ACC017, taken once daily alongside two other HIV medications (FTC/TAF), in adults with HIV-1 who have never been treated before. The goal is to see if ACC017 is as safe and effective as the current standard drug dolutegravir at lowering t…
Phase 1/2 • Sponsor: Jiangsu Aidea Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
First human test: can a new drug called ADB116 be given safely?
Knowledge-focused Recruiting nowThis early-stage trial is testing whether a single intravenous dose of an experimental drug called ADB116 is safe and tolerable in healthy Chinese adults aged 18 to 45. Researchers will monitor participants for side effects and measure how the drug moves through the body. The stu…
Phase 1 • Sponsor: Jiangsu Aidea Pharmaceutical Group Co., Ltd. • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC